All In Biotech

Drug Trial Radar · NCT00340080

Clinical Utility Of Genetic Screening For HLA-B*5701, On Susceptibility To Abacavir Hypersensitivity

A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*5701) for Susceptibility to Abacavir Hypersensitivity

Last checked: Nov 19, 2026Latest source record: Jan 25, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,806 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,806

Actual

Start

Apr 2006

Primary completion

Not stated

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jun 21, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study to evaluate the utility of prospective HLA-B\*5701 screening on the incidence of abacavir hypersensitivity (ABC HSR) in 1800 previously ABC-naive adults with HIV-1 from Europe, Australia and other countries as applicable. The study has two (co-primary) objectives: i) to determine if screening for HLA-B\*5701 prior to ABC-containing HAART results in a lower incidence of clinically-suspected HSR versus current standard of care (no genetic screening) and ii) to determine if screening for HLA-B\*5701 prior to ABC-containing HAART, results in a significantly lower incidence of immunologically-confirmed HSR versus current standard of care (no genetic screening or patch testing). The study consists of up to a 28-day screening period, a randomised observation period (Day 1 through Week 6) and, for subjects experiencing a suspected ABC HSR and a subset of ABC-tolerant subjects, an epicutaneous patch test (EPT) assessment period. Eligible subjects will be randomised to one of two study arms: a Current Standard of Care Arm (no prospective genetic screening: Control) and a Genetic Screening Arm (prospective genetic screening). Subjects identified as HLA-B\*5701 positive in the prospective Genetic Screening Arm will not receive ABC and will be excluded from further study. Subjects who experience suspected ABC HSR during the 6-week observation will be withdrawn from ABC-containing product and undergo EPT patch testing 6 weeks later.

Conditions

  • HIV Infection

Interventions

  • AbacavirDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of clinically-suspected ABC HSR during the 6-week observation period. Incidence of immunologically-confirmed ABC HSR. The clinical diagnosis of which occurs over the 6-week observation period.

Locations

254 sites in 19 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Darlinghurst, New South Wales, Australia

  • GSK Investigational Site

    Miami, Queensland, Australia

  • GSK Investigational Site

    Graz, Austria

  • GSK Investigational Site

    Innsbruck, Austria

  • GSK Investigational Site

    Linz, Austria

  • GSK Investigational Site

    Salzburg, Austria

  • GSK Investigational Site

    Vienna, Austria

  • GSK Investigational Site

    Bruges, Belgium

  • GSK Investigational Site

    Brussels, Belgium

  • GSK Investigational Site

    Brussels, Belgium

  • GSK Investigational Site

    Brussels, Belgium

  • GSK Investigational Site

    Brussels, Belgium

  • GSK Investigational Site

    Ghent, Belgium

  • GSK Investigational Site

    Leuven, Belgium

  • GSK Investigational Site

    Liège, Belgium

  • GSK Investigational Site

    Aix-en-Provence, France

  • GSK Investigational Site

    Amiens, France

  • GSK Investigational Site

    Angers, France

  • GSK Investigational Site

    Annecy, France

  • GSK Investigational Site

    Avignon, France

  • GSK Investigational Site

    Besançon, France

  • GSK Investigational Site

    Bobigny, France

  • GSK Investigational Site

    Bondy, France

  • GSK Investigational Site

    Bordeaux, France

  • GSK Investigational Site

    Bordeaux, France

  • GSK Investigational Site

    Caen, France

  • GSK Investigational Site

    Cannes, France

  • GSK Investigational Site

    Clermont-Ferrand, France

  • GSK Investigational Site

    Corbeil-Essonnes, France

  • GSK Investigational Site

    Créteil, France

  • GSK Investigational Site

    Dijon, France

  • GSK Investigational Site

    Fréjus, France

  • GSK Investigational Site

    Grenoble, France

  • GSK Investigational Site

    La Roche-sur-Yon, France

  • GSK Investigational Site

    La Rochelle, France

  • GSK Investigational Site

    Le Kremlin-Bicêtre, France

  • GSK Investigational Site

    Levallois-Perret, France

  • GSK Investigational Site

    Lyon, France

  • GSK Investigational Site

    Marseille, France

  • GSK Investigational Site

    Marseille, France

Showing 40 of 254 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.